All In MedTech

FDA Clearance Tracker · P990025-S002

NAVISTAR DEFLECTABLE TIP DIAGNOSTIC/ABLATION CATHETER

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 26, 2001 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 26, 2001

Approved

Time to decision

289 days

Received Dec 11, 2000. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class II

The decision

FDA number
P990025-S002
Device name
NAVISTAR DEFLECTABLE TIP DIAGNOSTIC/ABLATION CATHETER
Applicant location
Irvine, CA
Received
Dec 11, 2000
Decided
Sep 26, 2001
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P990025

Device type

Device class
Class II
Regulation
21 CFR 870.1220
Specialty
Cardiology

Every decision under product code DRF

FDA's approval statement

As written in FDA's record.

APPROVAL FOR EXPANDING THE INDICATIONS FOR USE. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME NAVISTART DEFLECTABLE TIP DIAGNOSTIC/ABLATION CATHETER AND IS INDICATED A FOLLOWS: THE BIOSENSE WEBSTER NAVI-STAR DIAGNOSTIC/ABLATION CATHETER, AND RELATED ACCESSORY DEVICES ARE INDICATED FOR CATHETER-BASED ATRIAL AND VENTRICULAR ELECTROPHYSIOLOGICAL MAPPING, AND FOR USE WITH A COMPATIBLE RF GENERATOR IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER IN CREATING ENDOCARDIAL LESIONS DURING CARDIAC ABLATION PROCEDURES TO TREAT ARRHYTHMIAS. WHEN USED WITH THE CARTO EP NAVIGATION SYSTEM, THE NAVI-STAR DIAGNOSTIC/ABLATION CATHETER PROVIDES LOCATION INFORMATION.

Source documents

Other decisions for Biosense Webster, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.